Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment o…
Biotechnology
US, South San Francisco [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Rigel Pharmaceuticals, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2015 | - | -5.700 | - | 5 | - | -991 | - | -2 | - | -2 | - | 5 |
| 2016 | - | -7.458 | - | 21 | - | -1,297 | - | -8 | - | -8 | - | 18 |
| 2017 | - | -5.660 | - | 4 | - | -984 | - | -1 | - | -1 | - | 3 |
| 2018 | - | -4.177 | - | 42 | - | -72 | - | -71 | - | -74 | - | 37 |
| 2019 | - | -3.778 | - | 59 | - | -72 | - | -71 | - | -75 | - | 52 |
| 2020 | - | -1.724 | - | 108 | - | -300 | - | -41 | - | -42 | - | 95 |
| 2021 | - | -1.023 | - | 150 | - | -177 | - | -57 | - | -58 | - | 133 |
| 2022 | - | -4.531 | - | 97 | - | -79 | - | -74 | - | -76 | - | 86 |
| 2023 | - | -1.701 | - | 114 | - | -25 | - | -82 | - | -83 | - | 106 |
| 2024 | - | 0.287 | - | 169 | - | 3 | - | -65 | - | -66 | - | 149 |
| 2025 | - | 0.977 | - | 193 | - | 20 | - | -74 | - | -75 | - | 171 |
| 2026 | - | 2.F11X/td> | - | 2.F11X/td> | - | 2.F11X/td> | - | 2.F111/td> | - | 2.F111 | - | 2.F111 |
| 2027 | - | 1.F12X/td> | - | 1.F12X/td> | - | 1.F12X/td> | - | 1.F121/td> | - | 1.F121 | - | 1.F121 |
| 2028 | - | 0.F13X/td> | - | 0.F13X/td> | - | 0.F13X/td> | - | 0.F131/td> | - | 0.F131 | - | 0.F131 |